A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency (GSID-E)
Primary Purpose
Genetic Sucrase-Isomaltase Deficiency
Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Sucraid
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Genetic Sucrase-Isomaltase Deficiency
Eligibility Criteria
Inclusion Criteria:
- Subject is 16 years of age or older.
- Subject is male or female. Women of childbearing potential must be willing to use one of the following contraception methods (for at least 10 days prior to start of study drug and for 10 to 14 days after last dose of study drug): Oral contraceptive, Injectable progestogen, Implants of levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device, Sterile male partner, Double-barrier method of contraception Women of non-child bearing potential include females regardless of age with functioning ovaries and who have a current tubal ligation (Hatcher, 2004), bilateral oophorectomy, or total hysterectomy, or post-menopausal females. Note: Post-menopausal is defined as 1 year without menses with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy).
- Subject has a minimum of 3 months of self-reported diarrhea (BSFS scores ≥ 5 on at least 3 days per week and ≥1 stool per day)
- Subject has a value in the SHMBT of at least 20 ppm for hydrogen, or 12 ppm for methane or 15 ppm above a previous breath sample for the combination of both gases.
- Subject reports that he/she experienced soft stools or diarrhea within the last 24 hours when contacted by the site 24 hours after completing the SHMBT.
- Subject is able to read, speak, and verbally understand the English language.
- Subject is located in the United States.
- Subject has access to the Internet on a daily basis.
- Subject has access to an acceptable Apple iPhone/iPad/iTouch or Android smartphone/tablet. The sponsor may choose to provide a smartphone in unusual cases (please contact sponsor to request loaner device when applicable)
Exclusion Criteria:
- Subject has recent history of functional or chronic constipation.
- Subject has known history of ulcerative colitis, Crohn's disease, or Celiac disease.
- Subject has known hypersensitivity to papain, glycerol, or yeast.
- Subject has received bovine serum in the last year.
- Subject has previous history of Sucraid use.
- Subject has taken any prebiotic or probiotic within 5 days prior to Visit 2 and does not agree to refrain from taking them during the study.
- Subject is female and is pregnant, breastfeeding, or planning to become pregnant during the study.
- Subject has known uncontrolled systemic disease.
- Subject has prior diagnosis of Type 1 or Type 2 diabetes.
- Subject has history of bowel resection.
- Subject is undergoing chemotherapy for the treatment of cancer.
- Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.
- Subject has used an investigational device or investigational drug within 30 days prior to Visit 1.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Treatment
Placebo
Arm Description
Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
Outcomes
Primary Outcome Measures
Response to Sucraid and placebo in a parallel group study based on improvement in daily stool consistency, as assessed by the BSFS using SHMBT
Response to Sucraid and placebo based on improvement in daily stool consistency, as assessed by the Bristol Stool Form Scale (BSFS) over a 1-week treatment period in subjects with chronic diarrhea and sucrase deficiency using a sucrose hydrogen methane breath test (SHMBT).
Secondary Outcome Measures
Effects of Sucraid and placebo on daily assessments of Bristol Stool Form Scale
Effects of Sucraid and placebo on daily stool frequency
Effects of Sucraid and placebo on daily abdominal pain
Effects of Sucraid and placebo on daily bloating severity
The relationship between the severity of sucrase deficiency, quantified by a SHMBT
The mean improvement in the BSFS for each treatment group.
Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants
Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants in comparison to the frequency in public proxy databases of broad populations.
The number of less common sucrase-isomaltase polymorphisms in this study population.
The allele frequency of the most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency in other databases
Assess the allele frequency of the 38 most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency of sucrase-isomaltase genetic variants in the Exome Variant Server, the ExAC server, and other public proxy and private genetic databases.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02784067
Brief Title
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
Acronym
GSID-E
Official Title
A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Clinical Trial Material
Study Start Date
May 2016 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
QOL Medical, LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
S09A is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel study examining the efficacy and safety of a Sucraid (sacrosidase) Oral Solution in comparison to a placebo in 150-200 subjects with chronic diarrhea possibly attributable to sucrase deficiency.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genetic Sucrase-Isomaltase Deficiency
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment
Arm Type
Experimental
Arm Description
Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
Intervention Type
Drug
Intervention Name(s)
Sucraid
Other Intervention Name(s)
Sacrosidase
Intervention Description
Study drug
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Sucraid placebo
Primary Outcome Measure Information:
Title
Response to Sucraid and placebo in a parallel group study based on improvement in daily stool consistency, as assessed by the BSFS using SHMBT
Description
Response to Sucraid and placebo based on improvement in daily stool consistency, as assessed by the Bristol Stool Form Scale (BSFS) over a 1-week treatment period in subjects with chronic diarrhea and sucrase deficiency using a sucrose hydrogen methane breath test (SHMBT).
Time Frame
Up to 2 years
Secondary Outcome Measure Information:
Title
Effects of Sucraid and placebo on daily assessments of Bristol Stool Form Scale
Time Frame
Up to 2 years
Title
Effects of Sucraid and placebo on daily stool frequency
Time Frame
Up to 2 years
Title
Effects of Sucraid and placebo on daily abdominal pain
Time Frame
Up to 2 years
Title
Effects of Sucraid and placebo on daily bloating severity
Time Frame
Up to 2 years
Title
The relationship between the severity of sucrase deficiency, quantified by a SHMBT
Time Frame
Up to 2 years
Title
The mean improvement in the BSFS for each treatment group.
Time Frame
Up to 2 years
Title
Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants
Description
Overall frequency of the 4 most common sucrase-isomaltase deficiency genetic variants in comparison to the frequency in public proxy databases of broad populations.
Time Frame
Up to 2 years
Title
The number of less common sucrase-isomaltase polymorphisms in this study population.
Time Frame
Up to 2 years
Title
The allele frequency of the most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency in other databases
Description
Assess the allele frequency of the 38 most common sucrase-isomaltase genetic variants in subjects with chronic diarrhea attributable to sucrase deficiency compared to the allele frequency of sucrase-isomaltase genetic variants in the Exome Variant Server, the ExAC server, and other public proxy and private genetic databases.
Time Frame
Up to 2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is 16 years of age or older.
Subject is male or female. Women of childbearing potential must be willing to use one of the following contraception methods (for at least 10 days prior to start of study drug and for 10 to 14 days after last dose of study drug): Oral contraceptive, Injectable progestogen, Implants of levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device, Sterile male partner, Double-barrier method of contraception Women of non-child bearing potential include females regardless of age with functioning ovaries and who have a current tubal ligation (Hatcher, 2004), bilateral oophorectomy, or total hysterectomy, or post-menopausal females. Note: Post-menopausal is defined as 1 year without menses with an appropriate clinical profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy).
Subject has a minimum of 3 months of self-reported diarrhea (BSFS scores ≥ 5 on at least 3 days per week and ≥1 stool per day)
Subject has a value in the SHMBT of at least 20 ppm for hydrogen, or 12 ppm for methane or 15 ppm above a previous breath sample for the combination of both gases.
Subject reports that he/she experienced soft stools or diarrhea within the last 24 hours when contacted by the site 24 hours after completing the SHMBT.
Subject is able to read, speak, and verbally understand the English language.
Subject is located in the United States.
Subject has access to the Internet on a daily basis.
Subject has access to an acceptable Apple iPhone/iPad/iTouch or Android smartphone/tablet. The sponsor may choose to provide a smartphone in unusual cases (please contact sponsor to request loaner device when applicable)
Exclusion Criteria:
Subject has recent history of functional or chronic constipation.
Subject has known history of ulcerative colitis, Crohn's disease, or Celiac disease.
Subject has known hypersensitivity to papain, glycerol, or yeast.
Subject has received bovine serum in the last year.
Subject has previous history of Sucraid use.
Subject has taken any prebiotic or probiotic within 5 days prior to Visit 2 and does not agree to refrain from taking them during the study.
Subject is female and is pregnant, breastfeeding, or planning to become pregnant during the study.
Subject has known uncontrolled systemic disease.
Subject has prior diagnosis of Type 1 or Type 2 diabetes.
Subject has history of bowel resection.
Subject is undergoing chemotherapy for the treatment of cancer.
Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.
Subject has used an investigational device or investigational drug within 30 days prior to Visit 1.
12. IPD Sharing Statement
Citations:
PubMed Identifier
5957725
Citation
Arthur AB. Intestinal disaccharidase deficiency in children with coeliac disease. Arch Dis Child. 1966 Oct;41(219):519-24. doi: 10.1136/adc.41.219.519. No abstract available.
Results Reference
background
PubMed Identifier
4885929
Citation
Bayless TM, Christopher NL. Disaccharidase deficiency. Am J Clin Nutr. 1969 Feb;22(2):181-90. doi: 10.1093/ajcn/22.2.181.
Results Reference
background
Citation
Chumpitazi BP, Robayo-Torres CC, Tsai CM, Opekun AR, Baker SS, Nichols BL, Gilger MA, Su1110 Yield of prospective disaccharidase testing in children with recurrent abdominal pain. Gastroenterology. May 2013;144(5):S-401-S402.
Results Reference
background
PubMed Identifier
1767818
Citation
Cross HS, Quaroni A. Inhibition of sucrose-isomaltase expression by EGF in the human colon adenocarcinoma cells Caco-2. Am J Physiol. 1991 Dec;261(6 Pt 1):C1173-83. doi: 10.1152/ajpcell.1991.261.6.C1173.
Results Reference
background
PubMed Identifier
2759730
Citation
Czernichow B, Simon-Assmann P, Kedinger M, Arnold C, Parache M, Marescaux J, Zweibaum A, Haffen K. Sucrase-isomaltase expression and enterocytic ultrastructure of human colorectal tumors. Int J Cancer. 1989 Aug 15;44(2):238-44. doi: 10.1002/ijc.2910440209.
Results Reference
background
PubMed Identifier
7973215
Citation
DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994 Jul 15-30;13(13-14):1341-52; discussion 1353-6. doi: 10.1002/sim.4780131308.
Results Reference
background
Citation
El-Chammas K, Williams S, Miranda A. Su1254 Lactase and sucrase deficiencies in pediatric subjects with chronic abdominal pain. Gastroenterology. May 2014;146(5):S-415-S416.
Results Reference
background
PubMed Identifier
10067723
Citation
Gupta SK, Chong SK, Fitzgerald JF. Disaccharidase activities in children: normal values and comparison based on symptoms and histologic changes. J Pediatr Gastroenterol Nutr. 1999 Mar;28(3):246-51. doi: 10.1097/00005176-199903000-00007.
Results Reference
background
Citation
Hatcher RA, Trussell J, Stewart F, Nelson AL, Cates W, Guest F, Kowal DD, editors. Contraceptive Technology. New York: Ardent Media, 2004:226.
Results Reference
background
PubMed Identifier
1904933
Citation
Heitlinger LA, Rossi TM, Lee PC, Lebenthal E. Human intestinal disaccharidase activities: correlations with age, biopsy technique, and degree of villus atrophy. J Pediatr Gastroenterol Nutr. 1991 Feb;12(2):204-8.
Results Reference
background
PubMed Identifier
7055778
Citation
Hyams JS, Batrus CL, Grand RJ, Sallan SE. Cancer chemotherapy-induced lactose malabsorption in children. Cancer. 1982 Feb 15;49(4):646-50. doi: 10.1002/1097-0142(19820215)49:43.0.co;2-m.
Results Reference
background
Citation
Kerry KR, & Townley, R. R. Genetic aspects of intestinal sucrase-isomaltase deficiency. Australian Paediatric Journal. 1965;1:223.
Results Reference
background
PubMed Identifier
11315085
Citation
Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999 Dec;55(4):1286-90. doi: 10.1111/j.0006-341x.1999.01286.x.
Results Reference
background
PubMed Identifier
21936724
Citation
Mones RL, Yankah A, Duelfer D, Bustami R, Mercer G. Disaccharidase deficiency in pediatric patients with celiac disease and intact villi. Scand J Gastroenterol. 2011 Dec;46(12):1429-34. doi: 10.3109/00365521.2011.619276. Epub 2011 Sep 22.
Results Reference
background
PubMed Identifier
11252408
Citation
Murray IA, Smith JA, Coupland K, Ansell ID, Long RG. Intestinal disaccharidase deficiency without villous atrophy may represent early celiac disease. Scand J Gastroenterol. 2001 Feb;36(2):163-8. doi: 10.1080/003655201750065915.
Results Reference
background
PubMed Identifier
23103647
Citation
Nichols BL Jr, Adams B, Roach CM, Ma CX, Baker SS. Frequency of sucrase deficiency in mucosal biopsies. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S28-30. doi: 10.1097/01.mpg.0000421405.42386.64. No abstract available.
Results Reference
background
PubMed Identifier
497341
Citation
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 Sep;35(3):549-56.
Results Reference
background
PubMed Identifier
15290663
Citation
Osterlund P, Ruotsalainen T, Peuhkuri K, Korpela R, Ollus A, Ikonen M, Joensuu H, Elomaa I. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2004 Aug;2(8):696-703. doi: 10.1016/s1542-3565(04)00293-9.
Results Reference
background
PubMed Identifier
18356321
Citation
Quezada-Calvillo R, Sim L, Ao Z, Hamaker BR, Quaroni A, Brayer GD, Sterchi EE, Robayo-Torres CC, Rose DR, Nichols BL. Luminal starch substrate "brake" on maltase-glucoamylase activity is located within the glucoamylase subunit. J Nutr. 2008 Apr;138(4):685-92. doi: 10.1093/jn/138.4.685.
Results Reference
background
Citation
Reed, JF. (2006) AB/BA Crossover Trials - Binary Outcome. J Modern Applied Stat Methods 5 (2): 452-457.
Results Reference
background
PubMed Identifier
23103658
Citation
Treem WR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S7-13. doi: 10.1097/01.mpg.0000421401.57633.90. No abstract available.
Results Reference
background
PubMed Identifier
9932843
Citation
Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42. doi: 10.1097/00005176-199902000-00008.
Results Reference
background
PubMed Identifier
8576798
Citation
Treem WR. Congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1995 Jul;21(1):1-14. doi: 10.1097/00005176-199507000-00001. No abstract available.
Results Reference
background
PubMed Identifier
8405850
Citation
Treem WR, Ahsan N, Sullivan B, Rossi T, Holmes R, Fitzgerald J, Proujansky R, Hyams J. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. Gastroenterology. 1993 Oct;105(4):1061-8. doi: 10.1016/0016-5085(93)90950-h.
Results Reference
background
PubMed Identifier
23103650
Citation
Uhrich S, Wu Z, Huang JY, Scott CR. Four mutations in the SI gene are responsible for the majority of clinical symptoms of CSID. J Pediatr Gastroenterol Nutr. 2012 Nov;55 Suppl 2:S34-5. doi: 10.1097/01.mpg.0000421408.65257.b5. No abstract available.
Results Reference
background
PubMed Identifier
25003680
Citation
Wiecek S, Wos H, Radziewicz Winnicki I, Komraus M, Grzybowska Chlebowczyk U. Disaccharidase activity in children with inflammatory bowel disease. Turk J Gastroenterol. 2014 Apr;25(2):185-91. doi: 10.5152/tjg.2014.3994.
Results Reference
background
Learn more about this trial
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
We'll reach out to this number within 24 hrs